GE Healthcare, the healthcare unit of General Electric (NYSE: GE), announced a strategic, long-term partnership with global pharmaceutical giant Roche (OTCQX: RHHBY) to jointly develop and market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
The partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio.
Medicine today is becoming vastly more data-driven due to advances in our scientific understanding of disease and human biology, combined with our ability to detect and measure many new parameters. In the process, it is also becoming a lot more complex for physicians, researchers, and patients to navigate and make sense of these data. Simply put, Roche Diagnostics and GE Healthcare intend to support these stakeholders in using all the available data to make better healthcare decisions. We do this by connecting the data silos that still exist in most clinical settings, providing collaboration tools and intuitive workflow products.
– Steve Burnell, PhD, VP, Head of Strategy, Diagnostics Information Solutions, Roche
The two companies aim to develop an industry-first digital platform, using advanced analytics to provide workflow solutions and apps that support clinical decisions. The goal is to enable seamless integration and analysis of the in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes, providing clinicians with vital decision support to dispense the right treatment and quality of care for their patients.
Source: GE Healthcare
This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree. We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.
– Kieran Murphy, President and CEO, GE Healthcare
Oncology care teams with multiple specialists will have a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, helping physicians to identify, or even predict severe complications before they strike.
This unique partnership will deliver innovative solutions and insights in clinical decision-making. Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.
– Roland Diggelmann, CEO Roche Diagnostics.